TransEnterix (NYSE:TRXC) announced today that it received CE Mark approval for its Intelligent Surgical Unit for the Senhance system.
The Intelligent Surgical Unit (ISU) enables machine vision capabilities on the Senhance surgical system, providing Senhance digital laparoscopic programs in Europe augmented intelligence capabilities in surgical settings, according to a news release. The FDA cleared the ISU in March 2020.
Research Triangle Park, N.C.-basd TransEnterix’s ISU platform is designed to recognize certain objects and locations in the surgical field, offering surgical teams improved collaboration by sharing the surgeon’s console view in real-time across the entire operating room.
Additionally, ISU features 3D point-to-point measurement and anatomical structure identification to enhance the digital laparoscopic experience with Senhance. ISU is compatible with Senhance and with third-party vision systems that are currently supported by Senhance.
“Augmented intelligence powered by machine vision will be one of the primary drivers in transforming surgery to enhance the capabilities of surgeons,” TransEnterix president & CEO Anthony Fernando said in the release. “We have already successfully implemented augmented intelligence in the U.S. with the Senhance System after receiving FDA clearance last year. We are pleased to expand this important capability to our broader global user base.”
The news comes days after robotic surgery company announced that it has raised $31 million from its latest stock offering.